Summary
Data guiding the appropriate management of patients with hepatic metastases arising from NE primaries, including pancreatic NE tumors, are limited. Long-term survival seems to be enhanced in those patients undergoing resection when it is done with a curative intent and potentially when per-formed as a debulking procedure. Symptoms, includ-ing those arising from hormone production, and pain are effectively treated with locally aggressive treatments including resection, thermal ablation, and tumor embolization. Given the lack of effective chemotherapy, the limited duration of response with hormonal therapy, the often indolent oncologic nature of these diseases, and the increasingly safe profile of these local options, locally aggressive treat-ments remain an important component of care.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sarmiento J, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendo-crine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003;197:29–37.
Jarnagin W, Gonen M, Fong YM, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 2002;236:397–407.
Hemming A, Reed A, Howard R, et al. Preoperative portal vein embolization for extended hepatectomy. Ann Surg 2003;237:686–691.
Adam R, Delvart V, Pascal G, et al. Rescue surgery for unre-sectable colorectal liver metastases downstaged by chemo-therapy: a model to predict long-term survival. Ann Surg 2004;240:644–657.
Chamberlain R, Canes D, Brown KT, et al. Hepatic neuro-edocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000;190:432–445.
Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 1997;187:88–93.
Norton J, Kivlen M, Li M, Schneider D, Chuter T, Jensen RT. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg 2003;138:859–866.
Routley D, Ramage JK, Mcpeake J, Tan KC, Williams R. Orthotopic liver transplantation in the treatment of meta-static neuroendocrine tumors of the liver. Liver Transpl Surg 1995;1:118–121.
Rosenau J, Bahr MJ, von Wasielewski R, et al. Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendo-crine tumors. Transplantation 2002;73:386–394.
Olausson M, Friman S, Cahlin C, et al. Indications and results of liver transplantation in patients with neuroendo-crine tumours. World J Surg 2002;26:998–1004.
Coppa J, Pulvirenti A, Schiavo M, et al. Resection versus transplantation for liver metastases from neuroendocrine tu-mors. Transplant Proc 2001;33:1537–1539.
Florman S, Toure B, Kim L, et al. Liver transplantation for neuroendocrine tumors. J Gastrointest Surg 2004;8:208–212.
Brown K, Koh BY, Brody LA, et al. Particle embolization of hepatic metastases for control of pain and hormonal symp-toms. J Vasc Interv Radiol 1999;10:397–403.
Goering J, Mahvi DM, Niederhuber JE, Chicks D, Rikkers LF. Cryoablation and liver resection for noncolorec-tal liver metastases. Am J Surg 2002;183:384–389.
Berber E, Flesher N, Siperstein A. Laparoscopic radiofre-quency ablation of neuroendocrine liver metastases. World J Surg 2002;26:985–990.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Clary, B. Treatment of isolated neuroendocrine liver metastases. J Gastrointest Surg 10, 332–334 (2006). https://doi.org/10.1016/j.gassur.2005.08.024
Issue Date:
DOI: https://doi.org/10.1016/j.gassur.2005.08.024